Skip to content

Evidence-based Evaluation Study and Predictive Model Establishment on Treatment of Refractory Gout with the Method of Transporting Spleen and Removing Dampness(Prospect)

Evidence-based Evaluation Study and Predictive Model Establishment on Treatment of Refractory Gout with the Method of Transporting Spleen and Removing Dampness(Prospect)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001278
Enrollment
Unknown
Registered
2025-06-26
Start date
2025-06-18
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

Western Medicine Section:Allopurinol 0.1 g/time, qd+Yunpi Huashi Granule Simulator 1 pack, bid
Integrated Traditional Chinese and Western Medicine Group:Allopurinol 0.1 g/time qd+Yunpi Huashi Granule 1 pack bid

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Those who meet the classification of gout and the diagnosis of refractory gout; 2) Those who meet the diagnosis of spleen deficiency and dampness-heat accumulation syndrome; 3) Age = 18 years old and = 65 years old, male or female; 4) The drugs that have not been used in the first 15 days and affect the observation of this test are selected; (5) Patients were informed and consented to participate in the study.

Exclusion criteria

Exclusion criteria: 1) Those with severe joint deformities multiple tophi all over the body with local ulceration; 2) Severe lesions of important organs or mental illness; 3) People who are allergic to or contraindicated from the use of the drugs involved in the study protocol; 4) Pregnant or breastfeeding patients; 5) HLA-B-5801 gene positive patients were clearly detected; 6) The investigator believes that the requirements for admission to this clinical trial are not met.

Design outcomes

Primary

MeasureTime frame
Blood uric acid fluctuation;

Secondary

MeasureTime frame
erythrocyte sedimentation rate;TCM syndrome score;C-reactive protein;Blood uric acid value;tongue coating score;Tophi reduction rate;Number of tophus;Blood uric acid compliance rate;Urate of Urate Crystal Deposition by Energy Spectrum CT;

Countries

China

Contacts

Public ContactHailong Wang

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

wanghailong@bucm.edu.cn18610185878

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026